Revvity, Inc. (NYSE:RVTY) shares are trading higher on Wednesday.
The company announced today that the U.S. Food and Drug Administration has approved its Auto-Pure 2400 liquid handling platform, integrated with the T-SPOT.TB test for latent tuberculosis detection.
First launched outside the U.S. in 2024, this combination is now available to improve laboratory productivity while maintaining superior clinical performance in TB testing.
The integration of the Auto-Pure 2400 system with the T-SPOT.TB test provides a high-throughput solution for laboratories, allowing them to process latent TB tests at a higher volume without compromising clinical accuracy.
The system can test up to 24 samples per run, completing Day 1 testing in under 3.5 hours with minimal user interaction.
Also Read: JPMorgan Hikes Recession Odds As Tariffs Create ‘A Dilemma For The Fed’
This efficiency is crucial in enhancing diagnostic speed and supporting timely TB treatment and containment.
The T-SPOT.TB test, recognized by the WHO as the only ELISPOT-based interferon-gamma release assay, ensures reproducible results with fewer indeterminate outcomes, making it especially reliable for immunocompromised patients.
Yves Dubaquie, senior VP of diagnostics at Revvity, highlighted that automating the process enables better patient outcomes through increased throughput and enhanced reliability.
“By automating T-SPOT.TB testing, we are empowering laboratories with increased throughput and reliability, ultimately leading to better patient outcomes,” Dubaquie added.
According to Benzinga Pro, RVTY stock has gained over 4% in the past year. Investors can gain exposure to the stock via T. Rowe Price Capital Appreciation Equity ETF (NYSE:TCAF).
Price Action: RVTY shares are trading higher by 2.48% to $106.90 at last check Wednesday.
Read now:
- Trump Tariffs Could Ignite Global Trade Shakeup: Betting Markets Price In Pain
Image via Shutterstock.
